Prasugrel for the treatment of patients with acute coronary syndrome

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 321-324

  Marzot, Filippo ^a   Pengo, Vittorio ^a  

^a Thrombosis Centre   (Italy)

Author keywords

Acute coronary syndrome; Oral antiplatelet agents; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450; DRUG METABOLITE; KETOCONAZOLE; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; R 138727; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLEEDING; BLOOD TOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEART CATHETERIZATION; HEART INFARCTION; HEMATOMA; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; QT PROLONGATION; REVIEW; RISK ASSESSMENT; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; CHEMICALLY INDUCED DISORDER; ORAL DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 67449085149     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234.
2. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurring events post-stenting. Results of the PREPARE POST-STENTING study. J Am Coll Cardiol. 2005;46:1820-1826.
3. Steinhubl PB, Berger JT, Mann III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;288:2411-2420.
4. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001;358:527-533.
5. Billet NH. Antiplatelet agents and arterial thrombosis. Cardiol Clin. 2008;26:189-201.
6. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48:1742-1750.
7. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49:2312-2317.
8. 12 receptor antagonist activity. Semin Thromb Hemost. 2005;31:184-194.
9. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129:1439-1446.
10. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35:1096-1104.
11. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent with the cytochromes P450. Drug Metab Dispos. 2006;34:600-607.
12. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429-2436.
13. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prsaugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007; 81:735-741.
14. Asai F, Jakubowski JA, Naganuma H, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single-ascending dose study in healthy humans. Platelets. 2006;17:209-217.
15. 12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharm. 2006;63:421-430.
16. 12 inhibitor: A multiple-dose study in healthy humans. Platelets. 2006;17:218-226.
17. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007; 153:66.e9-e16.
18. Jakubowski JA, Payne CD, Weerakkody GJ, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmocol. 2007;49:167-173.
19. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166-1173.
20. 12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilizationì of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111:3366-3373.
21. Wiviott SD, Braunwald E, McCabe CH, et al. A clinical trial of prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
22. Wiviott SD, Trenk D, Frelinger AL, et al; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-2932.